Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Inclusion Criteria

• •1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent.
• •2. Aged 18-75 years (inclusive).
• •3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •4. Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20.
• •5. At least one evaluable tumor lesion according to Lugano 2014 criteria.
• •Response to prior therapy is consistent with one of the following:
• •1. Primary refractory.
• •2. Relapsed or refractory after 2 or more lines of therapy.
• •3. For LBCL, 3B FL. t-iNHL:
• •* Relapse within 12 months after first-line chemoimmunotherapy to achieve CR;
• •* Progression or relapse within 12 months after autologous hematopoietic stem cell transplantation;
• •7\. Life expectancy≥ 3 months 8. Clinical laboratory values meet screening visit criteria